Tailored Therapy for Clarithromycin-Resistant H. Pylori

Efficacy Comparison of Metronidazole-based Triple and Bismuth-based Quadruple Therapy for Clarithromycin Resistant-Helicobacter Pylori Infection: Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03431688

Enrollment

782

Registered

2018-02-13

Start date

2018-10-01

Completion date

2020-12-30

Last updated

2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori Infection

Brief summary

Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure. Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recently, however, there have been few studies comparing treatment regimen in patient with clarithromycin-resistant H. pylori. We used sequencing-based clarithromycin resistance mutation and aimed to compare PAM (proton pump inhibitor, amoxicilline, metronidazole) regimen and PBMT (proton pump inhibitor, bismuth, metronidazole, tetracyclin) regimen in patient with clarithromycin-resistant H. pylori.

Interventions

DRUGPAM

treatment with PPI, metonidazole, amoxicillin

DRUGPBMT

treatment with PPI, metonidazole, bismuth, tetracyclin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

19 Years to 85 Years

Healthy volunteers

Inclusion criteria

* peptic ulcer disease * H. pylori gastritis * low grade MALT lymphoma

Exclusion criteria

* history of gastric cancer surgery * severe comorbidity (ESRD, LC) * hypersensitivity to drug * pregnancy

Design outcomes

Primary

Measure	Time frame	Description
H. pylori eradication rate	14 days	H. pylori eradication rate

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026